Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
figureposted on 2020-11-05, 10:30 authored by Aixin Shi, Panpan Xie, Lasse Lykke Nielsen, Trine Vang Skjøth, Xuemei He, Sine Pfeiffer Haugaard
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.